Premium
Autologous Cancer Vaccine: A Novel Formulation
Author(s) -
Ohno Tadao
Publication year - 2003
Publication title -
microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0385-5600
DOI - 10.1111/j.1348-0421.2003.tb03393.x
Subject(s) - adjuvant , hepatocellular carcinoma , cancer vaccine , cancer , vaccination , clinical trial , oncology , resection , medicine , biology , immunology , cancer research , surgery , immunotherapy
A novel cancer vaccine consisting of fixed autologous cancer tissue‐fragments, microparticles encapsulating cytokines, and an adjuvant was developed. In a Phase I/IIa clinical trial, vaccination to patients after resection of hepatocellular carcinoma induced significantly longer time before the first recurrence than that in historical control patients operated in the same department ( P <0.05). This formulation will be promising against recurrence of many types of human cancers.